Phathom Pharmaceuticals(PHAT)

Focus: Phathom is a public specialty pharmaceutical company focused on novel gastrointestinal disease treatments, with a market-leading acid reflux and H. pylori franchise centered on VOQUEZNA (vonoprazan fumarate).

Gastroenterology Neurology

Profile data last refreshed 9h ago · AI intelligence enriched 14h ago

Funding Stage

PUBLIC

Employees

51-200

Open Jobs

Should You Work at Phathom Pharmaceuticals?

AI assessment

A high-risk, high-reward opportunity for pharma professionals seeking early-stage commercial exposure in a focused GI franchise, but only if you can tolerate single-product dependency and pre-profitability volatility.

Why Work Here

Newly commercial company with 2025 revenue growing 8,000% YoY ($682K to $55M), offering early-stage commercialization experience in a growing franchise.

Data completeness

7/9 — Strong

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

3 in 5yr

VOQUEZNA

Hiring

Stable

Revenue

$55M

Key Products

VOQUEZNA

Gastroesophageal reflux and gastric acid disorders

$46K Part D

Growth

Help build intelligence for Phathom Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Strong cash position ($297M) and 62% R&D intensity enable meaningful pipeline expansion across multiple gastrointestinal indications beyond the lead product.

Focused gastroenterology platform with three Phase 3 programs in erosive esophagitis, H. pylori, and non-erosive GERD positions you at the center of a defined therapeutic strategy.

Watch Out For

Extreme revenue concentration (100% VOQUEZNA) and recent net loss of $334M in FY 2025 mean the company is entirely dependent on one drug's trajectory and profitability timeline remains unclear.
Single major patent cliff in 2030 with only $46K in Part D spending suggests VOQUEZNA adoption may still be ramping and commercial viability is not yet proven; restructuring risk is material if launch stalls.

Generated by Claude from Phathom Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Flagship monotherapy indication driving all current commercial revenue; early Part D spending suggests market acceptance is still ramping.

VOQUEZNA TRIPLE PAK

Helicobacter pylori eradication

Peak4.0yr

Fixed-dose combination for H. pylori infection; at peak lifecycle stage and likely contributing to revenue growth alongside monotherapy.

VOQUEZNA DUAL PAK

Helicobacter pylori eradication

Peak4.0yr

Alternative combination regimen for H. pylori; peak lifecycle indicates this formulation is part of the core commercial portfolio.

VOQUEZNA

Gastric acid suppression

Growth

Additional indication or market expansion for the core monotherapy; LOE date absence suggests potential for extended IP protection or newer formulation.

Pipeline & Clinical Trials

Vonoprazan

Erosive Esophagitis

N/A

Clinical Trials (1)

NCT06660342A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring

N/A

Vonoprazan

Healthy Participants

PHASE_1

Clinical Trials (1)

NCT04729101Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants

Phase 1

Vonoprazan ODT-1 or ODT-2 without Water

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT06831344A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

Phase 1

Vonoprazan

Erosive Esophagitis

PHASE_1

Clinical Trials (1)

NCT06391177A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily

Phase 1

Vonoprazan

Gastroesophageal Reflux Disease

PHASE_1

Clinical Trials (1)

NCT06106022A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease

Phase 1

Vonoprazan

Healthy Participants

PHASE_1

Clinical Trials (1)

NCT04558216Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants

Phase 1

Vonoprazan

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT05366738A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants

Phase 1

Vonoprazan

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT04545944Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants

Phase 1

Vonoprazan

Gastroesophageal Reflux

PHASE_1

Clinical Trials (1)

NCT05343364A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease

Phase 1

Vonoprazan

Eosinophilic Esophagitis

PHASE_2

Clinical Trials (1)

NCT06851559A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

Phase 2

Vonoprazan

Non-Erosive Gastro-Esophageal Reflux Disease

PHASE_2

Clinical Trials (1)

NCT04799158A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease

Phase 2

Vonoprazan

Helicobacter Pylori Infection

PHASE_3

Clinical Trials (1)

NCT04167670Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection

Phase 3

Vonoprazan

Non-Erosive Gastro-Esophageal Reflux Disease

PHASE_3

Clinical Trials (1)

NCT05195528A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

Phase 3

Vonoprazan

Erosive Esophagitis

PHASE_3

Clinical Trials (1)

NCT04124926Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

Phase 3

PYTEST® 14C-Urea Capsule Breath Test

H. Pylori Infection

PHASE_4

Clinical Trials (1)

NCT07224048Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2

Phase 4

PYTEST® 14C-Urea Breath Test

H Pylori Infection

PHASE_4

Clinical Trials (1)

NCT07224035Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1

Phase 4

Interview Prep Quick Facts

Portfolio: 4 approved products, 16 clinical trials

Top TAs: Gastroenterology, Oncology

Publications: 25 in PubMed

SEC Filings: 2 available

Open Roles: 1 active job

Portfolio Health

Growth2 (50%)

Peak2 (50%)

4 total products

Therapeutic Area Focus

Gastroenterology

5 pipeline

Oncology

2 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$55M8001%

R&D Spend

$34M(62%)32%

Net Income

-$334M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

The pharmacokinetics and safety of vonoprazan in adolescents and children with gastroesophageal reflux disease.

Journal of pediatric gastroenterology and nutrition

2026

PMID:41721637

Vonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Nonerosive Reflux Disease.

The American journal of gastroenterology

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Phathom Pharmaceuticals(PHAT)

Should You Work at Phathom Pharmaceuticals?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (3)

Pipeline & Clinical Trials

Recent News · Phathom Pharmaceuticals(10)

Open Jobs (1)

Intern

Financials (FY2025)

Hiring Trend

Research Publications(10)